These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19777735)

  • 21. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
    Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
    Pompili M; Serafini G; Innamorati M; Venturini P; Fusar-Poli P; Sher L; Amore M; Girardi P
    World J Biol Psychiatry; 2013 Aug; 14(6):412-31. PubMed ID: 23530731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
    Pandi-Perumal SR; Trakht I; Srinivasan V; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
    World J Biol Psychiatry; 2009; 10(4 Pt 2):342-54. PubMed ID: 18609422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agomelatine in the treatment of mood and anxiety disorders.
    Baldwin DS; Lopes AT
    Br J Hosp Med (Lond); 2010 Mar; 71(3):153-6. PubMed ID: 20220721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder.
    Lam RW
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S21-5. PubMed ID: 17917563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
    Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agomelatine in depressive disorders: its novel mechanisms of action.
    Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y; Gorwood P
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
    Lam RW
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction between the internal clock and antidepressant efficacy.
    Racagni G; Riva MA; Popoli M
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of antidepressants in clinical practice: focus on agomelatine.
    McAllister-Williams RH; Baldwin DS; Haddad PM; Bazire S
    Hum Psychopharmacol; 2010 Mar; 25(2):95-102. PubMed ID: 20196187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.